

From: [Tran, Frank](#)
To: ["Durbin, Christopher M"](#)
Subject: Request for additional information for NRC License No. 24-01570-03
Date: Friday, November 26, 2021 2:26:00 PM
Attachments: [Y-90 microspheres licensing guidance ML21089A364.pdf](#)

Dear Dr. Durbin:

We have reviewed your response dated October 13, 2021 associated with the license renewal application for NRC License No. 24-01570-03. Based on the review, we will need the following information.

1. Your current license is authorized for medical use of 10 CFR 35.300 material at 2345 Dougherty Ferry Rd., St. Louis, Missouri and 10 CFR 35.300 and 35.400 material at 232 S Woods Mill Rd., Chesterfield, Missouri. Please confirm if those material are for use with outpatients only. If they will be used for inpatients, please identify the rooms where they will be used and provide the followings: information about the type, thickness, and density of any necessary shielding to enable independent verification of shielding calculations, and a description of any portable shields used. The calculations should include the workload and conservative distance assumptions used.
2. You request to remove Item 6.M. (QSA Global GmbH Model SICW.3 sealed source) from the license. You indicated that the source was returned to the vendor. Please provide a copy of the receipt from the vendor and the last leak test record if applicable. In addition, please note that, based on the deletion of Item 6.M., we will delete all associated information related to the authorization of the NeoVista Epi-Rad90 Model R2.3 permitted by 10 CFR 35.1000 in the license.
3. In Item 6 of your response, you indicated the only change to License Condition 10 (authorized material and uses at each location) of the license is the addition of Y-90 microspheres to your license at 232 S Woods Mill Rd., Chesterfield, Missouri. Based on the NRC policy, please provide the information as discussed in the Yttrium-90 Microsphere Brachytherapy Sources and Devices TheraSphere® and SIR-Spheres® Licensing Guidance dated April 20, 2021. A copy of the guidance is attached for your reference.
4. Based on your response, we understand that you would like to delete the following users from the license: Daniel B. Bauwens, M.D., Amit K. Bhatt, M.D., Ph.D., Robert Kanterman, M.D., Cheryl Marcus, M.D., Anthony C. Pearson, M.D., and William Harms. If our understanding is incorrect, please let us know.
5. You request to add two additional authorized users to the license: Guillermo Gonzalez-Araiza, M.D. and Andrew L. Warren, M.D. Please specify what licensed material and uses you would like these individuals will be authorized for.

To continue the review of your application, we request that you submit your response under

a dated and signed cover letter by December 27, 2021. In the cover letter, please refer the license number, docket number and Mail Control No. 628104.

If you have questions, require additional time to respond, or require clarification on any of the information stated above, please contact me at 630-829-9623 or reply to this email.

In accordance with Title 10 of the *Code of Federal Regulations* (10 CFR) 2.390 of the NRC's "Rules of Practice," a copy of this correspondence will be made available electronically for public inspection in the NRC Public Document Room or from the NRC's Agencywide Documents Access and Management System (ADAMS), accessible from the NRC Web site at <https://www.nrc.gov/reading-rm/adams.html>.

Best regards,

Frank Tran

Health Physicist/License Reviewer
NRC Region III/Division of Nuclear Materials Safety
Phone: 630-829-9623
Fax: 630-515-1078
Email: Frank.Tran@nrc.gov

